Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Coverage and Use of Impella and Watchman: A Tale of Four Countries

Michael O'Riordan

March 04, 2025

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

Shelley Wood

May 06, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

Todd Neale

November 01, 2018

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

Advertisement

January 2026 Dispatch for the CV Team

Coverage and Use of Impella and Watchman: A Tale of Four Countries

June 2024 Dispatch for the CV Team

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FDA Approves Dapagliflozin for CKD Patients

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

FDA Gives Rivaroxaban Another VTE-Related Indication

FDA Expands TAVR Indication to Low-Risk Patients

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Betrixaban Approved for Prevention of VTE

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content